Literature DB >> 35814898

Evaluation of nintedanib as a new postoperative antiscarring agent in experimental extraocular muscle surgery.

Gozde Bicaklioglu1, Dilara Pirhan2, Yusufhan Yazir3,4, Gokhan Duruksu3, Selenay Furat Rencber4, Nursen Yuksel2.   

Abstract

AIM: To investigate the efficacy of nintedanib on reducing postoperative inflammation, fibrosis and adhesion formation following extraocular muscle surgery in rabbits in comparison with triamcinolone acetonide (TA).
METHODS: Reinsertion of superior rectus muscle in right eyes of 30 New Zealand white rabbits were performed. They were randomized to receive one of the following treatments: 0.9% normal saline, one of 1-, 5-, and 10 µmol doses of nintedanib subconjunctivally immediately after surgery and on postoperative day 1, 2, 3, 5, and 7, and TA immediately after surgery. As a control group, unoperated left eyes (n=6) were used. On the 28th day, six eyes from each group were enucleated and histopathologically and immunohistochemically analyzed to assess the postoperative inflammatory changes, fibrosis and adhesion. Transforming growth factor beta, matrix metalloproteinase-2 and alpha smooth muscle actin expressions were evaluated.
RESULTS: Conjunctival and scleral inflammation in TA and nintedanib groups were significantly reduced compared to saline (sham) group. Conjunctival vascularity and rectus muscle fibrosis were significantly reduced in 10 µmol nintedanib group. Nintedanib groups were the most effective groups in reduction of perimuscular fibrosis. Neither three nintedanib groups nor TA group differed statistically from sham group with regard to adhesion. The expressions of transforming growth factor beta, alpha smooth muscle actin and matrix metalloproteinase-2 were reduced in nintedanib groups compared to saline group.
CONCLUSION: Nintedanib appears to attenuate postoperative inflammation and fibrosis after extraocular muscle surgery. Nintedanib may be a safer and stronger alternative agent in extraocular muscle surgery when compared to steroids. Further investigation is needed to prove antiadhesive effect of nintedanib. International Journal of Ophthalmology Press.

Entities:  

Keywords:  extraocular muscle surgery; fibrosis; inflammation; nintedanib; triamcinolone acetonide

Year:  2022        PMID: 35814898      PMCID: PMC9203470          DOI: 10.18240/ijo.2022.06.08

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.645


  34 in total

Review 1.  Matrix metalloproteinase biology applied to vitreoretinal disorders.

Authors:  C S Sethi; T A Bailey; P J Luthert; N H Chong
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

2.  The use of amniotic membrane in reducing adhesions after strabismus surgery.

Authors:  Hosam Sheha; Victoria Casas; Yasutaka Hayashida
Journal:  J AAPOS       Date:  2008-10-30       Impact factor: 1.220

3.  Effects of mitomycin C on delayed adjustment in experimental strabismus surgery.

Authors:  S O Oh; B L Chang; J Lee
Journal:  Korean J Ophthalmol       Date:  1995-06

4.  Use of a silicone sheet for delayed adjustable strabismus surgery.

Authors:  M F Shokida
Journal:  Ophthalmic Surg       Date:  1993-07

5.  Histologic effect of mitomycin C on strabismus surgery in the rabbit.

Authors:  N Minguini; K M Monteiro de Carvalho; P M Akaishi; I M De Luca
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-10       Impact factor: 4.799

6.  Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.

Authors:  Lutz Wollin; Isabelle Maillet; Valérie Quesniaux; Alexander Holweg; Bernhard Ryffel
Journal:  J Pharmacol Exp Ther       Date:  2014-02-20       Impact factor: 4.030

7.  Effect of slow-releasing all-trans-retinoic acid in bioabsorbable polymer on delayed adjustable strabismus surgery in a rabbit model.

Authors:  Min Joung Lee; Su-Eon Jin; Chong-Kook Kim; Ho-Kyung Choung; Hwa Jung Kim; Jeong-Min Hwang
Journal:  Am J Ophthalmol       Date:  2009-07-09       Impact factor: 5.258

8.  BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.

Authors:  Frank Hilberg; Gerald J Roth; Martin Krssak; Susanna Kautschitsch; Wolfgang Sommergruber; Ulrike Tontsch-Grunt; Pilar Garin-Chesa; Gerd Bader; Andreas Zoephel; Jens Quant; Armin Heckel; Wolfgang J Rettig
Journal:  Cancer Res       Date:  2008-06-15       Impact factor: 12.701

9.  Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.

Authors:  Mareike Lehmann; Lara Buhl; Hani N Alsafadi; Stephan Klee; Sarah Hermann; Kathrin Mutze; Chiharu Ota; Michael Lindner; Jürgen Behr; Anne Hilgendorff; Darcy E Wagner; Melanie Königshoff
Journal:  Respir Res       Date:  2018-09-15

10.  Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis.

Authors:  Siri T Lehtonen; Anniina Veijola; Henna Karvonen; Elisa Lappi-Blanco; Raija Sormunen; Saara Korpela; Ulrika Zagai; Magnus C Sköld; Riitta Kaarteenaho
Journal:  Respir Res       Date:  2016-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.